FINWIRES · TerminalLIVE
FINWIRES

SGX:ULG

6 stories mentioning SGX:ULGUpdated 24d ago

Every FINWIRES story that references SGX:ULG, newest first.

What's the latest news on SGX:ULG?

Asia

Singapore Shares Remain in Red Despite Regional Gains; UltraGreen.ai Plunges 35%

Singapore shares remained rooted in the red zone on Thursday, despite regional gains as regional indices snapped their losing streaks.The Straits Times Index (STI), a key benchmark for the Singapore Exchange, ranged between 5,645.39 and 5,687.94 throughout the day. It ended the session at 5,671.91, down 22.33 points or 0.4% compared to Wednesday's close.On the corporate front, shares of UltraGreen.ai (SGX:ULG) plunged nearly 35% after it said there has been no material change to its business or outlook following US regulatory approvals for Zydus Lifesciences and Provepharm, which were highlighted in a Business Times article.Kimly (SGX:1D0) closed nearly 3% higher, with the coffee company looking to transfer from the Catalist board to the Mainboard of the Singapore Exchange.Meanwhile, iWOW Technology (SGX:NXR) said the final consideration for the acquisition of an entire stake in telecommunications solutions provider Roots Communications has been set at about SG$17.4 million.

^STISGX:1D0SGX:NXRSGX:ULG
Asia

UltraGreen.ai Maintains FY2026 Outlook Despite US Regulatory Nods; Shares Plunge 29%

UltraGreen.ai (SGX:ULG) said there has been no material change to its business or outlook following US regulatory approvals for Zydus Lifesciences and Provepharm, which were highlighted in a Business Times article, according to a filing with the Singapore Exchange.The company said Thursday that FDA approval does not necessarily result in commercial launches, market adoption, or market penetration, while assumptions about competitors' manufacturing costs and future pricing were based on third-party analysts' views.UltraGreen.ai maintained its FY2026 revenue guidance of $175 million to $185 million, with second-half revenue expected to exceed first-half revenue.Shares of the healthcare services company plunged 29% in recent trade.

SGX:ULG
Asia

UltraGreen.ai Receives Nod for Dual Currency Trading

UltraGreen.ai (SGX:ULG) received a no-objection notification from the Singapore Exchange Securities Trading for the trading of its shares on the dual currency trading platform of the bourse, according to a Friday stock exchange filing.Effective May 18, the pharmaceutical imaging and fluorescence-guided surgery company will commence trading of its shares in Singapore dollars, in addition to the US dollar.

SGX:ULG
Asia

Singapore Stocks Edge Down as Middle East Tensions Offset Upbeat Retail Data

Singapore shares incurred losses on Tuesday, mirroring regional losses as investors responded negatively to the possibility of the US and Iran returning to hostilities amid a fragile ceasefire.The Straits Times Index (STI), a key benchmark for the Singapore Exchange, ranged between 4,891.83 and 4,920.61 throughout the day. It ended the session at 4,920.61, down 3.70 points or 0.1% compared to Monday's close.In economic news, Singapore's total retail sales rose 4.8% year on year in March, following the 8.3% growth in the preceding month, according to data released by the Department of Statistics Singapore.On the corporate front, shares of UltraGreen.ai (SGX:ULG) dropped over 7% at the close as its total vial shipment fell 8.7% during the first quarter of the year to 280,900 vials from 307,600 vials a year earlier.Overseas-Chinese Banking Corp. or OCBC (SGX:O39) were hardly moved at the close, as it agreed to acquire the retail and wealth management business of HSBC's (HKG:0005) Indonesian arm.Meanwhile, shares of United Overseas Insurance (SGX:U13) were down under 1% as its insurance revenue dropped to SG$24.9 million in the first quarter of the year from SG$27.3 million a year earlier.

^STISGX:O39SGX:U13SGX:ULG
Asia

UltraGreen.ai Secures Regulatory OK for Indocyanine Green Injection in Singapore; Shares Down 5%

UltraGreen.ai (SGX:ULG) was granted regulatory approval in Singapore for Verdye, an indocyanine green injection, according to a Tuesday filing with the Singapore Exchange.The approval allows the company to ramp up its commercialization efforts and expand its partnerships with local healthcare institutions as part of the adoption of its fluorescence-guided technology.The technology is used across multiple surgical procedures.Shares of the healthcare intelligence company were down over 5% in Tuesday's late-morning trade.

SGX:ULG
Asia

UltraGreen.ai Vials Shipment Down 8.7% in Q1; Shares Plunge 5%

UltraGreen.ai's (SGX:ULG) total vial shipment fell 8.7% during the first quarter of the year to 280,900 vials from 307,600 vials a year earlier, according to a Tuesday filing with the Singapore Exchange.During the period, the healthcare intelligence company expanded its regulatory coverage to 41 countries.Shares of the company were down over 5% in Tuesday trading.

SGX:ULG

Track with the FINWIRES app suite

FolioX
FolioX
Track SGX:ULG in your portfolio
WheelAI
WheelAI
Analyze SGX:ULG options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SGX:ULG